AMMONIA N 13

Post-LOE

ammonia n 13

Apogee Biotechnology

ANDAINTRAVENOUSINJECTABLE

Approved

Sep 2020

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

AMMONIA N 13 (ammonia n 13) by Apogee Biotechnology is radiopharmaceutical activity [moa]. Approved for radioactive diagnostic agent [epc]. First approved in 2020.

Drug data last refreshed 18h ago

Mechanism of Action

Radiopharmaceutical Activity

Pharmacologic Class:

Radioactive Diagnostic Agent

Indications (1)

Radioactive Diagnostic Agent

Company

Worked on AMMONIA N 13 at Apogee Biotechnology? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.